These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36427338)

  • 1. Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis.
    Siddiqui ZA; Dhumal T; Patel J; LeMasters T; Almony A; Kamal KM
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1350-1364. PubMed ID: 36427338
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy.
    Ferrante N; Ritrovato D; Bitonti R; Furneri G
    BMC Health Serv Res; 2022 Apr; 22(1):573. PubMed ID: 35484540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
    Abraham I; Calamia M; Alkhatib N; Pondel M; MacDonald K
    J Med Econ; 2024; 27(sup3):9-23. PubMed ID: 39016811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 6. Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools.
    Hung A; Mullins CD; Slejko JF; Haines ST; Shaya F; Lugo A
    J Manag Care Spec Pharm; 2019 Mar; 25(3):342-349. PubMed ID: 30816818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration.
    Quist SW; de Jong LA; van Asten F; Knoester P; Postma MJ; Freriks RD
    Graefes Arch Clin Exp Ophthalmol; 2022 Apr; 260(4):1083-1095. PubMed ID: 34643793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration.
    Tadayoni R; Sararols L; Weissgerber G; Verma R; Clemens A; Holz FG
    Ophthalmologica; 2021; 244(2):93-101. PubMed ID: 33197916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis.
    Finger RP; Dennis N; Freitas R; Quenéchdu A; Clemens A; Karcher H; Souied EH
    Adv Ther; 2022 Aug; 39(8):3425-3448. PubMed ID: 35678996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens.
    Jiang B; Gao L; Dong S; Hou Q; Sun M; Zhang J; Yu H; Zhang Z; Sun D
    Adv Ther; 2022 Apr; 39(4):1568-1581. PubMed ID: 34817809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
    Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
    Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis.
    Almony A; Keyloun KR; Shah-Manek B; Multani JK; McGuiness CB; Chen CC; Campbell JH
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1260-1272. PubMed ID: 34464210
    [No Abstract]   [Full Text] [Related]  

  • 18. Budget impact analysis of biosimilar natalizumab in the US.
    Li E; Goh A; Gupta S; Schauf M; Chen A; Hartung DM
    Am J Manag Care; 2024 Jul; 30(7):e191-e197. PubMed ID: 38995822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan.
    Yanagi Y; Takahashi K; Iida T; Gomi F; Morii J; Kunikane E; Sakamoto T
    Ophthalmol Ther; 2023 Aug; 12(4):2005-2021. PubMed ID: 37171557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients.
    Mishra SK; Kumar P; Khullar S; Joshi A; Sati A; Kumar SV; Unni D; Kumar A
    Int J Retina Vitreous; 2022 Jul; 8(1):51. PubMed ID: 35902887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.